FDA accepts New Drug Application for mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

Submission for this investigational, oral, allosteric modulator of cardiac myosin, is based on data from phase 3 EXPLORER-HCM trial (n=251), which reported improvements in symptoms, functional status, quality of life and left ventricular outflow tract obstruction vs. placebo.

Source:

Biospace Inc.